{"id":"W2143695921","doi":"10.1200/jco.2007.14.4741","title":"Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":120,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada); Juravinski Cancer Centre; Princess Margaret Cancer Centre; Ottawa Hospital; Queen's University; University of Ottawa","funders":"","keywords":"Medicine; Paclitaxel; Vascular endothelial growth factor; Pharmacokinetics; Carboplatin; Tyrosine-kinase inhibitor; Tyrosine kinase; Kinase; Cancer research; VEGF receptors; Internal medicine; Lung cancer; Pharmacology; Oncology; Chemotherapy; Cancer; Receptor; Cisplatin; Biochemistry; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002074031,0.0001481113,0.001100726,0.00007338828,0.00002959677,0.000002592757,0.0001361976,0.000148709,0.000005990883],"category_scores_gemma":[0.0006540045,0.00009171075,0.00009296944,0.0001299875,0.0002824905,0.00002379326,0.00004326812,0.0002431752,3.840718e-9],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006672394,"about_ca_system_score_gemma":0.002027709,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01247231,"about_ca_topic_score_gemma":0.08163271,"domain_scores_codex":[0.9965009,0.0007539889,0.00201152,0.0002311571,0.000363546,0.000138864],"domain_scores_gemma":[0.9968104,0.0004048446,0.001963156,0.00009485105,0.0006149662,0.0001118164],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009695278,0.005604571,0.9672837,0.00005149447,0.000271369,0.00001310347,0.0001544238,0.0004192331,0.006867152,0.000003145251,0.00008855532,0.009547958],"study_design_scores_gemma":[0.06057407,0.02147582,0.9137301,0.00008759878,0.0002111701,0.000003483156,0.0001230073,0.0001911731,0.003097119,0.000003129713,0.0003775361,0.0001257883],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976842,0.001239317,0.0000295712,0.00007419324,0.0003008131,0.0005502135,0.0001126167,4.897307e-7,0.000008547599],"genre_scores_gemma":[0.9974327,0.001935942,0.0002511937,0.0001326858,0.0001995709,0.00002110713,0.00001071212,0.00001208128,0.000004018485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06916041,"threshold_uncertainty_score":0.9941037,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06787892216051723,"score_gpt":0.4164783429575141,"score_spread":0.3485994207969969,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}